Skip to main content
Erschienen in: Reactions Weekly 1/2012

01.09.2012 | Case report

Bevacizumab

Hypersensitivity: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Excerpt

Two men, aged 44 and 56 years, developed grade 2 hypersensitivity while receiving bevacizumab for metastatic colorectal cancer. …
Literatur
1.
Zurück zum Zitat Mahfoud T, Tanz R, Mesmoudi M, Khmamouche MR, Bazine A, Aassab R, Ismaili N, Boutayeb S, Ichou M, Errihani H.Bevacizumab 5 or 7.5 mg/kg in metastatic colorectal cancer can be infused safely over 10 minutes. Journal of Gastrointestinal Cancer 43: 244-248, No. 2, Jun 2012. Available from: URL: http://dx.doi.org/10.1007/s12029-010-9245-x - Morocco Mahfoud T, Tanz R, Mesmoudi M, Khmamouche MR, Bazine A, Aassab R, Ismaili N, Boutayeb S, Ichou M, Errihani H.Bevacizumab 5 or 7.5 mg/kg in metastatic colorectal cancer can be infused safely over 10 minutes. Journal of Gastrointestinal Cancer 43: 244-248, No. 2, Jun 2012. Available from: URL: http://​dx.​doi.​org/​10.​1007/​s12029-010-9245-x - Morocco
Metadaten
Titel
Bevacizumab
Hypersensitivity: 2 case reports
Publikationsdatum
01.09.2012
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2012
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.2165/00128415-201214200-00050

Weitere Artikel der Ausgabe 1/2012

Reactions Weekly 1/2012 Zur Ausgabe

Case report

Octreotide

Case report

Levetiracetam

Case report

Streptokinase